Cambridge, UK, October 2020: The o2h human health EIS Fund, is pleased to lead an investment into digital therapeutic Cortirio Limited alongside University of Surrey and KQ Labs. Traumatic brain injury is the leading cause of death and disability among the under 45s and a growing problem for our aging population as falls become more prevalent. Cortirio’s portable scanners can be used at the point of care to enable the early treatment of traumatic brain injuries. By saving time, this technology will save brain function and avert disability and death
Sunil Shah, CEO at o2h Ventures said:
“We are very excited to invest into Cortirio’s portable brain scanner. When fully developed this could be supportive to the NHS and to other health systems around the world”
Patrick Beldon, CEO and Co-Founder at Cortirio said:
“We are very happy to bring on o2h ventures as an investor as they are a value adding investor with the business and technology experience and global networks to help us commercialise our product.”
Caroline Fleming, Interim Director of Innovation Strategy at the University of Surrey said:
“The University of Surrey is excited to have developed an investment strategy to support pioneering businesses in the University’s Innovation Ecosystem. We are delighted with the growth we have seen Cortirio achieve since joining SETsquared Surrey and are pleased to contribute to the funding required to commercialise the Cortirio technology that can save lives and reduce NHS costs.”
About o2h ventures:
The o2h human health EIS Fund is the first S/EIS fund in the UK solely focused on investing in EIS and/or SEIS seed stage companies covering novel drug discovery & AI, digital therapeutics and enabling services.
The o2h team are leaders in the biotech community and have been actively involved as investors, holding various board/industry positions as well as being engaged in grassroots scientific activity for over 20 years. o2h ventures operates from their proprietary 2.7 acre Mill SciTech Park where they are developing a unique model for incubating small life science companies.
For more information or to invest in the fund, please visit www.o2hventures.com
Cortirio’s mission is to improve and save lives using medical imaging. Cortirio’s first application is for traumatic brain injuries, which kill 1 million people and leave 7.5 million people disabled each year. Fast treatment is vital for head injuries but 40% of all head injuries are not recognised within 12 hours. Cortirio is developing portable brain imaging which can be used at the scene of an injury to reduce time-to-treatment and save lives.
For more information, please visit http://cortirio.com